Acute Lung Injury-Pipeline Insights, 2014 - with 50% Discount

1
Acute Lung Injury-Pipeline Insights, 2014 - with
50 Discount
One-Stop Shop for Business Information
2
Summary
SUMMARY 'Acute Lung Injury-Pipeline Insights,
2014', report provides comprehensive insights
about pipeline drugs across this indication. A
key objective of the report is to establish the
understanding for all the pipeline drugs that
fall under Acute Lung Injury. This report
provides information on the therapeutic
development based on the Acute Lung Injury
dealing with all the pipeline drugs, comparative
analysis at various stages covering Filed, Phase
III, Phase II, Phase I, IND filed, Preclinical,
Discovery and unknown stages, therapeutics
assessment by monotherapy and combination
products and molecule type drug information. The
report also covers the companies information
involved in the therapeutic development of the
products. It also has highlighted the
discontinued and dormant products.
3
Secondary sources information and data has been
collected from various printable and
non-printable sources like search engines, News
websites, Government Websites, Trade Journals,
White papers, Magazines, Trade associations,
Books, Industry Portals, Industry Associations
and access to available databases. Scope The
report provides a snapshot of the global
therapeutic landscape of Acute Lung Injury
The report provides pipeline products under drug
profile section which includes product
description, MOA, licensors collaborators,
development partner and chemical
information Coverage of the Acute Lung Injury
pipeline on the basis of target, MOA, route
of administration, technology involved and
molecule type
4
The report reviews key players involved in the
therapeutics development for Acute Lung
Injury and also provide company profiling The
report also gives the information of dormant and
discontinued pipeline projects Pipeline
products coverage based on various stages of
development ranging from preregistration till
discovery and undisclosed stages Provides
pipeline assessment by monotherapy and
combination therapy products, stage of
development and molecule type Reasons to buy
Complete Pipeline intelligence and complete
understanding over therapeutics development
for Acute Lung Injury Identify the relationship
between the drugs and use it for target finding,
drug repurposing, and precision medicine.
5
Devise corrective measures for pipeline
projects by understanding Acute Lung Injury
pipeline depth and focus of Indication
therapeutics Developing strategic initiatives
to support your drug development activities.
Optimize your portfolio and keep you in touch
with the rapidly changing pharmaceutical
markets, and make the best decisions for your
business. Develop and design in licensing and
out licensing strategies by identifying
prospective partners with the most attractive
projects to enhance and expand business
potential and scope Provides strategically
significant competitor information, analysis, and
insights to formulate effective RD
development strategies Modify the therapeutic
portfolio by identifying discontinued projects
and understanding the factors that drove them
from pipeline Gaining a Full Picture of the
Competitive Landscape for Evidence based
Decisions
6
Table Of Content
Acute Lung Injury Overview Acute Lung Injury
Pipeline Therapeutics Acute Lung Injury
Therapeutics under Development by Companies
Acute Lung Injury Late Stage Products (Filed and
Phase III) Comparative Analysis Acute Lung
Injury Mid Clinical Stage Products (Phase II)
Comparative Analysis Acute Lung Injury Early
Clinical Stage Products (Phase I and IND Filed)
Comparative Analysis Acute Lung Injury
Discovery and Pre-Clinical Stage Products
Comparative Analysis Drug Candidate Profiles
Acute Lung Injury Therapeutics Assessment
Assessment by Monotherapy Products Assessment
by Combination Products
7

• To know more Acute Lung Injury-Pipeline
  Insights, 2014

Contact Us-Call India 91-22-27810772/73 Call
USA/Canada (Toll Free) 1-866-279-8368 Email id
info_at_bharatbook.com